Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We recently reiterated our Neutral recommendation on Onyx Pharmaceuticals, Inc. . Onyx Pharma is engaged in the development of novel cancer therapies that target the molecular basis of the disease.

Why the Reiteration?

Onyx Pharma has successfully transformed itself from a single-product company to a multi-product company. With two new product launches, Kyprolis and Stivarga, and Nexavar continuing to perform well, Onyx Pharma looks well-positioned. We expect 2013-2014 to be catalyst-rich as the company works on expanding the labels of currently marketed products and progresses with the development of other candidates.

Kyprolis and Stivarga represent significant commercial potential. However, Kyprolis is facing competition from Celgene’s (CELG - Analyst Report) Pomalyst. Moreover, Kyprolis revenues were slightly soft during the recently reported second quarter of 2013.

Onyx Pharma has been in the news of late given biotech major Amgen’s (AMGN - Analyst Report) interest in acquiring the company. In Jun 2013, Onyx Pharma rejected a $120 per share takeover bid from Amgen. Management stated that the offer significantly undervalued the company. Onyx Pharma is, however, still interested in selling itself and is on the lookout for potential bidders. On its second quarter 2013 conference call, the company announced that it is currently in discussions with several interested parties - we believe an acquisition deal could be announced soon.

Other Stocks to Consider

At present, Biogen Idec (BIIB - Analyst Report) looks well-positioned with a Zacks Rank #1 (Strong Buy). Biogen’s recently launched multiple sclerosis drug, Tecfidera, is off to a strong start. Biogen raised its 2013 outlook again. Key products, Avonex and Tysabri, should continue contributing significantly to sales. Tecfidera should help drive long-term growth.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%